ONDINE BIOMEDICAL INC.CDI Total Liabilities
ONDINE BIOMEDICAL INC.CDI total liabilities. Based on the latest financial reports, ONDINE BIOMEDICAL INC.CDI (VF5) has total liabilities worth €5.95 Million EUR (≈ $6.95 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ONDINE BIOMEDICAL INC.CDI (VF5) liquidity interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of ONDINE BIOMEDICAL INC.CDI (2021–2024)
Total liabilities of ONDINE BIOMEDICAL INC.CDI from 2021 to 2024. This chart illustrates how ONDINE BIOMEDICAL INC.CDI's total liabilities have evolved over time, based on quarterly financial data.
ONDINE BIOMEDICAL INC.CDI Competitors by Total Liabilities
The table below lists competitors of ONDINE BIOMEDICAL INC.CDI ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RingNet Co. Ltd
KQ:042500
|
Korea | ₩42.63 Billion |
|
Yenher Holdings Bhd
KLSE:5300
|
Malaysia | RM42.25 Million |
|
NTPM Holdings Bhd
KLSE:5066
|
Malaysia | RM484.30 Million |
|
American Creek Resources Ltd
V:AMK
|
Canada | CA$30.45K |
|
Icure Pharmaceutical Incorporation
KQ:175250
|
Korea | ₩80.55 Billion |
|
Nam Liong Global Corp
TWO:5450
|
Taiwan | NT$1.72 Billion |
|
Playstudios Inc
NASDAQ:MYPS
|
USA | $60.23 Million |
|
Lithium Chile Inc
V:LITH
|
Canada | CA$6.54 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down ONDINE BIOMEDICAL INC.CDI's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of ONDINE BIOMEDICAL INC.CDI.
Liquidity & Leverage Metrics
ONDINE BIOMEDICAL INC.CDI Total Liabilities Ratios Explained
ONDINE BIOMEDICAL INC.CDI total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ONDINE BIOMEDICAL INC.CDI's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ONDINE BIOMEDICAL INC.CDI (2021–2024)
The table below shows the annual total liabilities of ONDINE BIOMEDICAL INC.CDI from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €5.95 Million ≈ $6.95 Million |
+62.92% |
| 2023-12-31 | €3.65 Million ≈ $4.27 Million |
-25.91% |
| 2022-12-31 | €4.92 Million ≈ $5.76 Million |
+9.86% |
| 2021-12-31 | €4.48 Million ≈ $5.24 Million |
-- |
About ONDINE BIOMEDICAL INC.CDI
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, … Read more